Athersys to Participate in Advanced Therapies Week and Allogeneic Cell Therapies Summit Europe in January - Seite 3

About MultiStem

MultiStem (invimestrocel) cell therapy is a patented regenerative medicine product in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors in response to signals of inflammation and tissue damage. MultiStem therapy’s potential for multidimensional therapeutic impact distinguishes it from traditional biopharmaceutical therapies focused on a single mechanism of benefit. The therapy represents a unique "off-the-shelf" stem cell product that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression. Based upon its efficacy profile, its novel mechanisms of action, and a favorable and consistent tolerability demonstrated in clinical studies, we believe that MultiStem therapy could provide a meaningful benefit to patients, including those suffering from serious diseases and conditions with unmet medical need.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005756/en/

The Athersys Stock at the time of publication of the news with a fall of -11,03 % to 1,210USD on Nasdaq stock exchange (11. Januar 2023, 17:47 Uhr).